Evidence map›Paper›PMID 27981493›Full record

ArticleJournal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract2017

Conversion Surgery Post-Intraperitoneal Paclitaxel and Systemic Chemotherapy for Gastric Cancer Carcinomatosis Peritonei. Are We Ready?

Dexter Yak Seng Chan, Nicholas Li-Xun Syn, Rachel Yap, Janelle Niam Sin Phua, Thomas I Peng Soh, Cheng Ean Chee, Min En Nga, Asim Shabbir, Jimmy Bok Yan So, Wei Peng Yong

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05395910 (Phase 1 Study of Pressurized IntraPeritoneal Aerosol Chemotherapy), which is not on this map. Cited by 35 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05395910 phase1unknown statusnot on this mapstarted 2023, after this paper: background citation

Phase 1 Study of Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) and Electrostatic PIPAC (ePIPAC) With Paclitaxel for Peritoneal Carcinomatosis - PIPAC2 Study

TypeinterventionalSponsorNational University Hospital, SingaporeRan2023 to 2025Enrolled36ConditionsPeritoneal CarcinomatosisArmsPaclitaxel
3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.

  1. Chemotherapy for advanced gastric cancer.The Cochrane database of systematic reviews · 2017
    Pooled it
  2. Trial
  3. Intraperitoneal paclitaxel plus intravenous fluorouracil, leucovorin, oxaliplatin (FOLFOX) and nivolumab for gastric cancer with peritoneal metastasis: results from the IPLUS Phase II study.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026
    Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Oncological outcomes of conversion therapy in gastric cancer patients with peritoneal metastasis: a large-scale retrospective cohort study.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2024
    Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Integration of Genomic Biology Into Therapeutic Strategies of Gastric Cancer Peritoneal Metastasis.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022
    Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Dexter Yak Seng ChanDepartment of Surgery, National University Health System, 1E Kent Ridge Road, NUHS Tower Block, Level 8, Singapore, 119228, Singapore.
Nicholas Li-Xun SynDepartment of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore.
Rachel YapDepartment of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore.
Janelle Niam Sin PhuaDepartment of Surgery, National University Health System, 1E Kent Ridge Road, NUHS Tower Block, Level 8, Singapore, 119228, Singapore.
Thomas I Peng SohDepartment of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore.
Cheng Ean CheeDepartment of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore.
Min En NgaDepartment of Pathology, National University Health System, Singapore, Singapore.
Asim ShabbirDepartment of Surgery, National University Health System, 1E Kent Ridge Road, NUHS Tower Block, Level 8, Singapore, 119228, Singapore.
Jimmy Bok Yan SoDepartment of Surgery, National University Health System, 1E Kent Ridge Road, NUHS Tower Block, Level 8, Singapore, 119228, Singapore. jimmy_so@nuhs.edu.sg.
Wei Peng YongDepartment of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore.
National University Health System · SGNational University Cancer Institute, Singapore · SGNational University of Singapore · SG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Peritoneal metastasis is common in gastric cancer. It is difficult to treat and carries a poor prognosis. Intraperitoneal (IP) delivery of chemotherapy can attain a higher drug exposure in the peritoneal cavity but with reduced systemic toxicity. Therefore, we hypothesized that IP paclitaxel with systemic chemotherapy would be clinically beneficial for gastric cancer with peritoneal metastases. Patients with unresectable and/or recurrent gastric adenocarcinoma with peritoneal dissemination and/or positive peritoneal washing cytology were recruited. They underwent eight cycles of IP paclitaxel and systemic XELOX. The primary endpoint was 1-year overall survival rate and secondary endpoints were safety, response rate, and peritoneal cytological response. Patients who subsequently had no distant metastases and two consecutive negative peritoneal cytologies underwent conversion gastrectomy if there was no macroscopic evidence of peritoneal disease at diagnostic laparoscopy. Twenty-two patients were enrolled, receiving at least one cycle of IP paclitaxel at the time of reporting (data cutoff-March 11, 2016). The median number of cycles was 7.5. The median overall survival was 18.8 months, and the 1-year survival rate was 72.2%. One patient died of neutropenic sepsis. Of 19 evaluable patients with measurable disease, 7 (36.8%) achieved PR, 8 (42.1%) achieved SD, and 4 (21.1%) experienced PD. Peritoneal cytology turned negative in 11 of 17 (64.7%) patients. Six patients underwent conversion gastrectomy (4 R0, 2 R1) with a median survival of 21.6 months (range = 8.7-29.9 months). XELOX and IP paclitaxel appears to be an effective regimen in gastric cancer with peritoneal metastases. Conversion gastrectomy may be considered in patients with a favorable response.

Indexed as

AdenocarcinomaAgedAntineoplastic Combined Chemotherapy ProtocolsCapecitabineCarcinomaDeoxycytidineFemaleFluorouracilGastrectomyHumansInfusions, ParenteralMaleMiddle AgedOxaloacetatesPaclitaxelPeritoneal NeoplasmsCapecitabineDeoxycytidineFluorouracilOxaloacetatesPaclitaxelGastric cancerIntraperitoneal chemotherapyPeritoneal metastases

Identifiers

PMID27981493
OpenAlexW2562042133

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.